期刊
CANCER CELL
卷 25, 期 4, 页码 442-454出版社
CELL PRESS
DOI: 10.1016/j.ccr.2014.02.010
关键词
-
资金
- National Institutes of Health [T32-HL007088, CA162086, CA101937]
- Barnes Jewish Hospital Foundation
- National Institute of General Medical Sciences [8 P41 GM103422-35]
- National Cancer Institute [P30 CA091842]
- National Center for Advancing Translational Sciences [UL1 TR000448]
Somatic mutations in DNMT3A, which encodes a de novo DNA nnethyltransferase, are found in similar to 30% of normal karyotyp,e acute myeloid leukemia (AML) cases. Most mutations are heterozygous and alter R882 within the catalytic domain (most commonly R882H), suggesting the possibility of dominant-negative consequences. The methyltransferase activity of R882H DNMT3A is reduced by similar to 80% compared with the WT enzyme. In vitro mixing of WT and R882H DNMT3A does not affect the WT activity, but coexpression of the two proteins in cells profoundly inhibits the WT enzyme by disrupting its ability to homotetramerize. AML cells with the R882H mutation have severely reduced de novo nnethyltransferase activity and focal hypomethylation at specific CpGs throughout AML cell genomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据